Clinical trial · Observational
Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion
Study on the Prediction Model of Recurrence and Carcinogenesis Risk of Colorectal Adenoma Based on the Fusion of Traditional Chinese and Western Medicine Multimodal Features
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project focuses on developing a risk prediction model for the recurrence and malignant transformation of colorectal adenomas by integrating multimodal features from both Traditional Chinese Medicine (TCM) and Western medicine. Led by Dr. Wei Hongtao from Beijing Friendship Hospital, Capital Medical University, the primary objective is to mine clinical characteristics from both medical systems to construct a robust predictive model. The research encompasses several key aspects: a multicenter, large-sample cohort study design with a clearly defined sample size and calculation basis; patient recruitment from multiple institutions nationwide to form training and validation sets; and strict adherence to standardized TCM and Western diagnostic criteria. Through comprehensive observation of demographic, TCM clinical (e.g., syndromes, tongue and pulse diagnosis), and Western clinical features, the study ensures data accuracy via rigorous monitoring and follow-up. Various algorithms are employed to extract and analyze these multi-source features-including endoscopic data-to build and evaluate the prediction model. Furthermore, the study aims to identify dominant subgroups to optimize TCM intervention strategies. Key performance indicators include establishing the risk model, identifying target populations, publishing high-quality papers, and training graduate students. By innovatively constructing this multimodal fusion model, the project provides a novel perspective and evidence-based foundation for the prevention and treatment of colorectal adenomas using TCM.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Control and Prevention | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Colorectal Adenoma
- description
- Patients diagnosed with colorectal adenoma who have undergone endoscopic resection (including endoscopic mucosal resection \[EMR\], endoscopic submucosal dissection \[ESD\], or cold snare polypectomy \[CSP\], as appropriate for lesion characteristics) and whose resected specimen has been pathologically confirmed as colorectal adenoma (excluding adenocarcinoma, hyperplastic polyps, or other non-adenomatous lesions) are eligible for enrollment.
Primary outcomes (1)
- measure
- Advanced Adenoma Recurrence
- timeFrame
- From enrollment to study completion, up to 3 years (average 1.5 years)
Secondary outcomes (1)
- measure
- Adenoma Recurrence
- timeFrame
- From enrollment to study completion, up to 3 years (average 1.5 years)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Meet the diagnostic criteria for colorectal adenoma (Western medicine) and the relevant TCM syndromes. * Aged 18 years or older. * Willing to undergo regular follow-up examinations (including colonoscopy and laboratory tests) and sign the informed consent form. Exclusion Criteria: * Pregnant or lactating women. * History of Crohn's disease, ulcerative colitis, or other malignancies. * Previous history of radiotherapy, chemotherapy, or gastrointestinal surgery. * Hereditary polyposis syndromes (e.g., familial adenomatous polyposis, MUTYH-associated polyposis, or hamartomatous polyposis syndrome). * Severe cognitive impairment, dementia, or mental illness. * Severe cardiovascular or cerebrovascular diseases, or hematological system disorders.
References
Publications (6)
- RESULTWang RJ, Zhang XL, Cai JD, Wang MH, Liu JQ, Xu Y. [Standardized diagnosis and treatment of colorectal polyps]. Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Jun 25;27(6):583-590. doi: 10.3760/cma.j.cn441530-20240416-00143. Chinese. PMID 38901991
- RESULTRoslan NH, Makpol S, Mohd Yusof YA. A Review on Dietary Intervention in Obesity Associated Colon Cancer. Asian Pac J Cancer Prev. 2019 May 25;20(5):1309-1319. doi: 10.31557/APJCP.2019.20.5.1309. PMID 31127882
- RESULTTerasaki M, Kubota A, Kojima H, Maeda H, Miyashita K, Kawagoe C, Mutoh M, Tanaka T. Fucoxanthin and Colorectal Cancer Prevention. Cancers (Basel). 2021 May 14;13(10):2379. doi: 10.3390/cancers13102379. PMID 34069132
- RESULTKanth P, Inadomi JM. Screening and prevention of colorectal cancer. BMJ. 2021 Sep 15;374:n1855. doi: 10.1136/bmj.n1855. PMID 34526356
- RESULTKim SH, Park DH, Lim YJ. Impact of Diet on Colorectal Cancer Progression and Prevention: From Nutrients to Neoplasms. Korean J Gastroenterol. 2023 Aug 25;82(2):73-83. doi: 10.4166/kjg.2023.079. PMID 37621242
- RESULTZhou E, Rifkin S. Colorectal Cancer and Diet: Risk Versus Prevention, Is Diet an Intervention? Gastroenterol Clin North Am. 2021 Mar;50(1):101-111. doi: 10.1016/j.gtc.2020.10.012. PMID 33518157